|1.||Gauthier, Serge: 15 articles (01/2015 - 12/2002)|
|2.||Burns, Alistair: 11 articles (12/2015 - 03/2003)|
|3.||Zhang, Richard: 11 articles (02/2011 - 01/2003)|
|4.||Cummings, Jeffrey L: 10 articles (05/2013 - 01/2006)|
|5.||Bullock, Roger: 10 articles (06/2009 - 03/2002)|
|6.||Mori, Etsuro: 9 articles (01/2015 - 04/2005)|
|7.||Meguro, Kenichi: 9 articles (01/2015 - 04/2008)|
|8.||Wilkinson, David: 9 articles (11/2014 - 11/2004)|
|9.||Mackell, Joan: 9 articles (01/2013 - 01/2010)|
|10.||Xu, Yikang: 9 articles (12/2011 - 06/2005)|
|1.||Alzheimer Disease (Alzheimer's Disease)
01/01/2004 - "Despite a sense of limited efficacy of this drug class among prescribers, number needed-to-treat analyses suggest donepezil is highly effective at reducing the long-term adverse outcomes associated with Alzheimer's disease."
01/01/2013 - "Excessive sleepiness was reported to be altered in four studies, however the only clinically and statistically significant change in ESS of -2.9 (SD 2.9; P = 0.04) along with a small but statistically significant reduction in AHI of -9.4 (SD 17.2; P = 0.03) was seen in patients without Alzheimer's disease receiving donepezil for one month. "
10/01/2000 - "There have been a number of randomised, placebo-controlled trials of donepezil in the treatment of mild-moderate Alzheimer's disease and these report significant benefits for a proportion of patients. "
03/01/2000 - "Donepezil 5 and 10 mg/day significantly improved cognition and global clinical function compared with placebo in well designed short term trials (14 to 30 weeks) in 161 to 818 patients with mild to moderate Alzheimer's disease. "
06/01/2013 - "The Alzheimer's disease assessment scale score showed significant improvement after dose escalation of donepezil (P = 0.006). "
01/01/2015 - "Among anti-dementia drugs, donepezil showed significantly greater protective effects than placebo regarding %TBV/y (SMD=-0.43, 95%CI=-0.74 to -0.12, P=.007, N=1, n=164) and %VV/y (SMD=-0.51, 95%CI=-0.73 to -0.29, P<.00001, N=2, n=338). "
06/01/2010 - "Thus, the early diagnosis of dementia and prompt initiation of donepezil treatment is indicated for a good outcome. "
12/01/2001 - "Patients treated with donepezil maintained or improved in cognition and overall dementia severity in contrast to placebo-treated patients who declined during the 6-month treatment period. "
01/01/2006 - "Treatment with donepezil was only effective in PD patients with dementia, who experience nearly no side effects from the drug."
08/01/2005 - "Donepezil appears to be effective in the treatment of cognitive and behavioural disturbances associated with the progressive dementia syndrome in Down's. "
|3.||Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
08/01/2009 - "Donepezil-treated patients with Binswanger type subcortical vascular dementia demonstrated significant improvement in cognition compared with baseline, and donepezil was well tolerated."
03/01/2004 - "Donepezil minimally effective for patients with vascular dementia."
03/01/2010 - "To determine the long-term tolerability and efficacy of donepezil in patients with vascular dementia (VaD). "
10/01/2003 - "Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial."
10/01/2007 - "To study the efficacy and safety of the combined treatment with compound Reinhartdt and Sea Cumber Capsule (RSC, a Chinese medicinal preparation consisted mainly of Reinhartdt and Sea Cumber) and Donepezil for vascular dementia (VD), and its effect on thyroid function axis. "
|4.||Schizophrenia (Dementia Praecox)
01/01/2014 - "The results of the present study suggest that adjunctive use of donepezil is beneficial for improving cognitive function in patients with schizophrenia. "
12/12/2008 - "The purpose of this study was to assess the efficacy of donepezil as an adjuvant agent in the treatment of chronic schizophrenia in particular for cognitive impairments. "
09/01/2006 - "We tested the efficacy of donepezil in elderly patients with chronic schizophrenia and severe cognitive impairment. "
09/01/2005 - "[Efficacy of adjunctive donepezil for cognitive impairments in patients with schizophrenia]."
01/01/2014 - "The aim of the present study was to evaluate the effects of adjunctive treatment with donepezil on cognition in patients with chronic schizophrenia. "
|5.||Parkinson Disease (Parkinson's Disease)
01/01/2013 - "Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP)."
01/01/2015 - "Using pooled datasets from phase 2 and 3, 12-week randomized, placebo-controlled trials (RCT, n = 281) and 52-week open-label long-term extension trials (OLE, n = 241) of donepezil in DLB, the effects of donepezil on the incidence of extrapyramidal adverse events (AEs) and on the Unified Parkinson's Disease Rating Scale (UPDRS) part III were assessed, and potential baseline factors affecting the AEs were explored. "
01/01/2004 - "Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease."
06/01/2002 - "Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study."
10/21/2015 - "Donepezil Regulates 1-Methyl-4-phenylpyridinium-Induced Microglial Polarization in Parkinson's Disease."
|4.||Cholinesterase Inhibitors (Anticholinesterases)
|8.||Ginkgo biloba extract 761 (Rokan)
|1.||Activities of Daily Living (ADL)
|3.||Palliative Care (Palliative Medicine)
|4.||Drug Therapy (Chemotherapy)
|5.||Home Nursing (Nursing, Home)